Teijin Limited and Japan Tissue Engineering Co., Ltd. announced that they have entered into a Letter of Intent for a global strategic collaboration with Resilience US Inc. to enhance contract development and manufacturing organization capabilities for cell and gene therapies, including regenerative medicines, to customers in North America and Asia- Pacific (APAC). Teijin, J-TEC and Resilience intend to mutually support and facilitate the expansion of their clients' businesses to the respective regions. Resilience would serve as one of the preferred suppliers and manufacturers to Teijin and J-TEC's customers for North America-based process and analytical development (PAD) and biomanufacturing and refer Teijin and J- TEC for APAC-based PAD and biomanufacturing.

In addition, Resilience would serve as One of the preferred suppliers of viral vectors for use in the development and manufacture of cell and gene therapy products. Together, the three companies aim to accelerate development and production of new manufacturing technologies related to cell and gene therapies, and regenerative medicines. Additionally, the companies will discuss a cross-licensing arrangement to enable each party to use the other party's proprietary manufacturing platforms and related technology in their home jurisdiction, Japan or North America, as applicable.

The development of preferred clinical trial and regulatory pathways for the companies' customers in Japan and North America is also under discussion. Demand for CDMO services in cell and gene therapies, including Regenerative medicines, is rising due to heightened technical levels in manufacturing and specialization in manufacturing and development functions. Demand for regenerative medicine market is rapidly growing and is estimated to exceed JPY 850 billion in 2030 in Japan.

This trend is assumed to result in increase of regenerative medicine products originated outside Japan in the Japanese market, making a system that connects development demand between Japan and outside Japan vital.